{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T05:19:07Z","timestamp":1787548747021,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Objective<\/jats:title>\n This study aimed to investigate the association between the Prognostic Nutritional Index (PNI) and the prognosis of advanced esophageal squamous cell carcinoma (ESCC) patients treated with immune checkpoint inhibitors (ICIs).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively analyzed the clinical data of 157 advanced ESCC patients who received ICIs therapy at Hengshui People\u2019s Hospital. The PNI was calculated based on serum albumin levels and lymphocyte counts. The predictive value of PNI for disease progression in advanced ESCC patients was evaluated using receiver operating characteristic (ROC) curve analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 157 patients with advanced ESCC, the complete response (CR) rate was 0.64% (1\/157), partial response (PR) rate was 47.13% (74\/157), stable disease (SD) rate was 38.22% (60\/157), and progressive disease (PD) rate was 14.01% (22\/157). The median progression-free survival (PFS) was 14.2 months. During the follow-up period, 80 patients died, leading to a mortality rate of 50.96%. The CR+PR group showed significantly higher albumin levels, lymphocyte counts, and PNI compared to the PD group (\n p<\/jats:italic>\n &lt;\u00a00.05). The area under the curve (AUC) of PNI for predicting disease progression was 0.770 (95% CI: 0.696-0.833), with a sensitivity of 86.36% and specificity of 58.52%. Based on the cutoff value, patients were stratified into high-PNI (&gt;44.4, n=82) and low-PNI (ow-PNI n=75) groups. The high-PNI group demonstrated significantly lower disease progression rates compared to the low-PNI group (\n p<\/jats:italic>\n &lt;\u00a00.05). Kaplan-Meier analysis revealed that advanced ESCC patients in the high-PNI group had significantly longer PFS and overall survival (OS) than those in the low-PNI group (\n p<\/jats:italic>\n &lt;\u00a00.05). The disease-free survival rate after ICIs therapy was 96.34% in the high-PNI group compared to 74.67% in the low-PNI group (Log-rank \u03c7\u00b2=18.332,\n p<\/jats:italic>\n &lt;\u00a00.05). The 3-year survival rate post-ICIs was 64.93% in the high-PNI group compared to 33.75% in the low-PNI group (Log-rank \u03c7\u00b2=12.378,\n p<\/jats:italic>\n &lt;\u00a00.05). Lymphocyte count and PNI as independent prognostic factors for PFS in advanced ESCC patients (\n p<\/jats:italic>\n &lt;\u00a00.05), while poor differentiation, smoking history, and PNI were independent predictors for OS (\n p<\/jats:italic>\n &lt;\u00a00.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n PNI is associated with the efficacy of ICI therapy and prognosis in patients with advanced ESCC, suggesting its potential as a promising prognostic stratification marker. However, the clinical utility of PNI as an independent biomarker requires further validation through prospective, multicenter studies with larger sample sizes.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1764557","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:18Z","timestamp":1787545458000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic nutritional index in evaluating the prognosis of ICIs in patients with advanced esophageal squamous carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Qingfang","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hengshui People\u2019s Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hengshui People\u2019s Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hengshui People\u2019s Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun\u2019e","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hengshui People\u2019s Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hengshui People\u2019s Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114328","article-title":"Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): a single-arm, phase II study","volume":"212","author":"Meng","year":"2024","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100380","article-title":"Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score","volume":"7","author":"Leone","year":"2022","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12876-022-02296-9","article-title":"Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy","volume":"22","author":"Qian","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.13207","article-title":"Prognostic nutritional index as a predictor of prognosis in postoperative patients with gastric cancer","volume":"37","author":"Ishiguro","year":"2023","journal-title":"In Vivo"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1213255","article-title":"Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors","volume":"10","author":"Yan","year":"2023","journal-title":"Front Nutr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109496","article-title":"Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients","volume":"114","author":"Xu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e008942","DOI":"10.1136\/jitc-2024-008942","article-title":"Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study","volume":"12","author":"Feng","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5816","article-title":"Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1177085","article-title":"Radiotherapy combined with immune checkpoint inhibitors in locally advanced\/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219929","article-title":"Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"17272","DOI":"10.1038\/s41598-023-43391-5","article-title":"Preoperative albumin-to-globulin ratio and prognostic nutritional index predict the prognosis of colorectal cancer: a retrospective study","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202210_30045","article-title":"The prognostic role of albumin-bilirubin grade in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"26","author":"Shi","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1472","article-title":"Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors","volume":"12","author":"Saal","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s12885-025-14060-9","article-title":"Peripheral blood inflammatory biomarkers neutrophil\/ lymphocyte ratio, platelet\/lymphocyte ratio and systemic immune-inflammation index\/albumin ratio predict prognosis and efficacy in non-small cell lung cancer patients receiving immunotherapy and opioids","volume":"25","author":"Lei","year":"2025","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01822-6","article-title":"Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer","volume":"127","author":"Elomaa","year":"2022","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.3390\/cancers15194771","article-title":"Dual functions of T lymphocytes in breast carcinoma: from immune protection to orchestrating tumor progression and metastasis","volume":"15","author":"Zareinejad","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01035-y","article-title":"Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta-analysis","volume":"23","author":"Kou","year":"2023","journal-title":"Clin Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231202921","article-title":"Effect of peripheral blood lymphocytes on prognosis of multiple cancers","volume":"30","author":"Zhang","year":"2023","journal-title":"Cancer Control"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104216","article-title":"Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint","volume":"83","author":"Verma","year":"2022","journal-title":"EBioMedicine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/medicina61040715","article-title":"Prognostic impact of Klintrup-M\u00e4kinen (KM) score in gastric cancer and its association with pathological parameters","volume":"61","author":"Cozac-Sz\u0151ke","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/10668969241291882","article-title":"Clinicopathological characteristics of neutrophil-rich hepatocellular carcinoma: an uncommon subtype of primary liver cancer","volume":"33","author":"Vij","year":"2025","journal-title":"Int J Surg Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1422160","article-title":"Effect of smoking status on immunotherapy for lung cancer: a systematic review and meta-analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764557\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:24:19Z","timestamp":1787545459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764557\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1764557"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1764557","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1764557"}}